Generic Lotronex Availability
LOTRONEX (alosetron hydrochloride - tablet; oral)
Manufacturer: PROMETHEUS LABS
Approval date: February 9, 2000
Strength(s): EQ 1MG BASE [RLD]
Manufacturer: PROMETHEUS LABS
Approval date: December 23, 2003
Strength(s): EQ 0.5MG BASE
Has a generic version of Lotronex been approved?
No. There is currently no therapeutically equivalent version of Lotronex available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lotronex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: November 1, 1994
Inventor(s): Coates; Ian H. & North; Peter C. & Oxford; Alexander W.
Assignee(s): Glaxo Group Limited
The invention relates to tricyclic lactams of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenyl C.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl or phenoxymethyl, one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkhyl group; n represents 2 or 3; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.Patent expiration dates:
- January 13, 2013✓✓✓
- January 13, 2013
Medicaments for the treatment of non-constipated female irritable bowel syndrome
Issued: September 4, 2001
Inventor(s): Mangel; Allen Wayne & Northcutt; Allison Ruth
Assignee(s): Glaxo Wellcome Inc.
This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.Patent expiration dates:
- October 5, 2018✓
- October 5, 2018
- Lotronex Consumer Information (Drugs.com)
- Lotronex Consumer Information (Wolters Kluwer)
- Lotronex Consumer Information (Cerner Multum)
- Lotronex Advanced Consumer Information (Micromedex)
- Lotronex AHFS DI Monographs (ASHP)
- Alosetron Consumer Information (Wolters Kluwer)
- Alosetron Consumer Information (Cerner Multum)
- Alosetron Advanced Consumer Information (Micromedex)
- Alosetron Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|